174 related articles for article (PubMed ID: 38061261)
1. Regulation of tau by peptidyl-prolyl isomerases.
Zhuang S; Chakraborty P; Zweckstetter M
Curr Opin Struct Biol; 2024 Feb; 84():102739. PubMed ID: 38061261
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer's disease.
Blair LJ; Baker JD; Sabbagh JJ; Dickey CA
J Neurochem; 2015 Apr; 133(1):1-13. PubMed ID: 25628064
[TBL] [Abstract][Full Text] [Related]
3. Function and regulation of cis P-tau in the pathogenesis and treatment of conventional and nonconventional tauopathies.
Wang R; Lu KP; Zhou XZ
J Neurochem; 2023 Sep; 166(6):904-914. PubMed ID: 37638382
[TBL] [Abstract][Full Text] [Related]
4. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
[TBL] [Abstract][Full Text] [Related]
5. Human cyclophilin 40 unravels neurotoxic amyloids.
Baker JD; Shelton LB; Zheng D; Favretto F; Nordhues BA; Darling A; Sullivan LE; Sun Z; Solanki PK; Martin MD; Suntharalingam A; Sabbagh JJ; Becker S; Mandelkow E; Uversky VN; Zweckstetter M; Dickey CA; Koren J; Blair LJ
PLoS Biol; 2017 Jun; 15(6):e2001336. PubMed ID: 28654636
[TBL] [Abstract][Full Text] [Related]
6. Pinning down phosphorylated tau and tauopathies.
Lim J; Lu KP
Biochim Biophys Acta; 2005 Jan; 1739(2-3):311-22. PubMed ID: 15615648
[TBL] [Abstract][Full Text] [Related]
7. Computational perspective and evaluation of plausible catalytic mechanisms of peptidyl-prolyl cis-trans isomerases.
Ladani ST; Souffrant MG; Barman A; Hamelberg D
Biochim Biophys Acta; 2015 Oct; 1850(10):1994-2004. PubMed ID: 25585011
[TBL] [Abstract][Full Text] [Related]
8. Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.
Ando K; Dourlen P; Sambo AV; Bretteville A; Bélarbi K; Vingtdeux V; Eddarkaoui S; Drobecq H; Ghestem A; Bégard S; Demey-Thomas E; Melnyk P; Smet C; Lippens G; Maurage CA; Caillet-Boudin ML; Verdier Y; Vinh J; Landrieu I; Galas MC; Blum D; Hamdane M; Sergeant N; Buée L
Neurobiol Aging; 2013 Mar; 34(3):757-69. PubMed ID: 22926167
[TBL] [Abstract][Full Text] [Related]
9. Bending tau into shape: the emerging role of peptidyl-prolyl isomerases in tauopathies.
Koren J; Jinwal UK; Davey Z; Kiray J; Arulselvam K; Dickey CA
Mol Neurobiol; 2011 Aug; 44(1):65-70. PubMed ID: 21523562
[TBL] [Abstract][Full Text] [Related]
10. Multidomain Peptidyl Prolyl cis/trans Isomerases.
Schiene-Fischer C
Biochim Biophys Acta; 2015 Oct; 1850(10):2005-16. PubMed ID: 25445709
[TBL] [Abstract][Full Text] [Related]
11. Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies.
Venkatramani A; Panda D
Int J Biol Macromol; 2019 Jul; 133():473-483. PubMed ID: 31004638
[TBL] [Abstract][Full Text] [Related]
12. Isomerase Pin1 stimulates dephosphorylation of tau protein at cyclin-dependent kinase (Cdk5)-dependent Alzheimer phosphorylation sites.
Kimura T; Tsutsumi K; Taoka M; Saito T; Masuda-Suzukake M; Ishiguro K; Plattner F; Uchida T; Isobe T; Hasegawa M; Hisanaga SI
J Biol Chem; 2013 Mar; 288(11):7968-7977. PubMed ID: 23362255
[TBL] [Abstract][Full Text] [Related]
13. Insights into the catalytic mechanism of peptidyl prolyl cis/trans isomerases.
Fanghänel J; Fischer G
Front Biosci; 2004 Sep; 9():3453-78. PubMed ID: 15353370
[TBL] [Abstract][Full Text] [Related]
14. [Unexpected roles of the peptidyl-prolyl cis/trans isomerase Pin1].
Lavoie SB; Albert AL; Vincent M
Med Sci (Paris); 2003 Dec; 19(12):1251-8. PubMed ID: 14691750
[TBL] [Abstract][Full Text] [Related]
15. Peptidyl-prolyl isomerases: functionality and potential therapeutic targets in cardiovascular disease.
Rostam MA; Piva TJ; Rezaei HB; Kamato D; Little PJ; Zheng W; Osman N
Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):117-24. PubMed ID: 25377120
[TBL] [Abstract][Full Text] [Related]
16. Introduction to Peptidyl-Prolyl cis/trans Isomerase (PPIase) Series.
Galat A
Biomolecules; 2019 Feb; 9(2):. PubMed ID: 30791666
[TBL] [Abstract][Full Text] [Related]
17. The Multiple Roles of Peptidyl Prolyl Isomerases in Brain Cancer.
Stifani S
Biomolecules; 2018 Oct; 8(4):. PubMed ID: 30314361
[TBL] [Abstract][Full Text] [Related]
18. Tauopathies.
Hernández F; Avila J
Cell Mol Life Sci; 2007 Sep; 64(17):2219-33. PubMed ID: 17604998
[TBL] [Abstract][Full Text] [Related]
19. Microbial peptidyl-prolyl cis/trans isomerases (PPIases): virulence factors and potential alternative drug targets.
Ünal CM; Steinert M
Microbiol Mol Biol Rev; 2014 Sep; 78(3):544-71. PubMed ID: 25184565
[TBL] [Abstract][Full Text] [Related]
20. Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.
Yotsumoto K; Saito T; Asada A; Oikawa T; Kimura T; Uchida C; Ishiguro K; Uchida T; Hasegawa M; Hisanaga SI
J Biol Chem; 2009 Jun; 284(25):16840-16847. PubMed ID: 19401603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
